Vasiliki Alevras-Sztukowski, OD
Corneal and Contact Management · Centennial, CONPI 1851477681
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alcon at 29.2% of the total.
Across 45 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$297
- Coopervision Inc.$273
- Bausch & Lomb Americas Inc.$140
- Johnson & Johnson Vision Care, Inc.$136
- Bausch & Lomb, A Division Of Bausch Health US, LLC$59
- Novartis$48
- plus $64 from 2 others
What the payments were for
- Food & beverage$1,017100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $297 |
| Coopervision Inc. | 11 | $273 |
| Bausch & Lomb Americas Inc. | 6 | $140 |
| Johnson & Johnson Vision Care, Inc. | 8 | $136 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $59 |
| Novartis | 2 | $48 |
| Oyster Point Pharma, Inc. | 2 | $45 |
| Harrow Eye, LLC | 1 | $19 |
How this compares
$1,017 in reported general payments places this provider in the 65th percentile of 33 corneal and contact management providers in Colorado.
See all corneal and contact management providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 15 | $10,049 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,745 |
| Prednisolone Acetate | 11 | $632 |
| Latanoprost | 40 | $413 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in Centennial
- John SchachetCentennial$8K
- Jon PedersonCentennial$754
- Paul ConklingCentennial$64
- Ryan SmedleyWestminster$88K
- Natalie SantelliFort Collins$5K
- Sarah BellParker$4K
- Grant SchanemanJohnstown$4K
- Kevin AndersonFt Collins$2K
- Jerry BellParker$2K
- Larry EklundWellington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.